The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population-A comparison of two German registries.

Autor:	Hasseli R; Section of Rheumatology and Clinical Immunology, Department of Internal Medicine D, University Hospital Münster, Münster, Germany.; Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Giessen, Germany., Hanses F; Emergency Department and Department for Infectious Diseases and Infection Control, University Hospital Regensburg, Regensburg, Germany., Stecher M; Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Specker C; Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, Germany., Weise T; Biocontrol Jena, Jena, Germany., Borgmann S; Department of Infectious Diseases and Infection Control, Ingolstadt Hospital, Ingolstadt, Germany., Hasselberger M; Klinikum Passau, Passau, Germany., Hertenstein B; Klinikum Bremen-Mitte, Bremen, Germany., Hower M; Department of Pneumology, Infectious Diseases, Internal Medicine and Intensive Care, Klinikum Dortmund GmbH, Dortmund, Germany., Hoyer BF; Department for Rheumatology and Clinical Immunology, University of Schleswig-Holstein, Kiel, Germany., Koll C; Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany., Krause A; Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital Berlin, Berlin, Germany., von Lilienfeld-Toal M; Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany., Lorenz HM; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Merle U; Department of Gastroenterology and Infectious Diseases, Heidelberg University Hospital, Heidelberg, Germany., Nunes de Miranda SM; Department of Medicine II, University of Freiburg, Freiburg, Germany., Pletz MW; Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany., Regierer AC; Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany., Richter JG; Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany.; Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine-University, Düsseldorf, Germany., Rieg S; Division of Infectious Diseases, Department of Medicine II, University of Freiburg, Freiburg, Germany., Roemmele C; Department of Gastroenterology, Faculty of Medicine, University of Augsburg, Augsburg, Germany., Ruethrich MM; Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany., Schmeiser T; Private Practice, Cologne, Germany., Schulze-Koops H; Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany., Strangfeld A; Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany., Vehreschild MJGT; Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany., Voit F; Department of Internal Medicine II, School of Medicine, University Hospital Rechts Der Isar, Technical University of Munich, Munich, Germany., Voll RE; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany., Vehreschild JJ; Department I of Internal Medicine, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.; Department II of Internal Medicine, Hematology/Oncology, Goethe University, Frankfurt, Germany., Müller-Ladner U; Department of Rheumatology and Clinical Immunology, Justus-Liebig University Giessen, Giessen, Germany., Pfeil A; Department of Internal Medicine III, University Hospital Jena, Jena, Germany.
Jazyk:	angličtina
Zdroj:	Frontiers in medicine [Front Med (Lausanne)] 2024 Mar 06; Vol. 11, pp. 1332716. Date of Electronic Publication: 2024 Mar 06 (Print Publication: 2024).
DOI:	10.3389/fmed.2024.1332716
Abstrakt:	Objectives: To investigate, whether inflammatory rheumatic diseases (IRD) inpatients are at higher risk to develop a severe course of SARS-CoV-2 infections compared to the general population, data from the German COVID-19 registry for IRD patients and data from the Lean European Survey on SARS-CoV-2 (LEOSS) infected patients covering inpatients from the general population with SARS-CoV-2 infections were compared. Methods: 4310 (LEOSS registry) and 1139 cases (IRD registry) were collected in general. Data were matched for age and gender. From both registries, 732 matched inpatients (LEOSS registry: n = 366 and IRD registry: n = 366) were included for analyses in total. Results: Regarding the COVID-19 associated lethality, no significant difference between both registries was observed. Age > 65°years, chronic obstructive pulmonary disease, diabetes mellitus, rheumatoid arthritis, spondyloarthritis and the use of rituximab were associated with more severe courses of COVID-19. Female gender and the use of tumor necrosis factor-alpha inhibitors (TNF-I) were associated with a better outcome of COVID-19. Conclusion: Inflammatory rheumatic diseases (IRD) patients have the same risk factors for severe COVID-19 regarding comorbidities compared to the general population without any immune-mediated disease or immunomodulation. The use of rituximab was associated with an increased risk for severe COVID-19. On the other hand, the use of TNF-I was associated with less severe COVID-19 compared to the general population, which might indicate a protective effect of TNF-I against severe COVID-19 disease. Competing Interests: TW was employed by company Biocontrol Jena. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision. (Copyright © 2024 Hasseli, Hanses, Stecher, Specker, Weise, Borgmann, Hasselberger, Hertenstein, Hower, Hoyer, Koll, Krause, von Lilienfeld-Toal, Lorenz, Merle, Nunes de Miranda, Pletz, Regierer, Richter, Rieg, Roemmele, Ruethrich, Schmeiser, Schulze-Koops, Strangfeld, Vehreschild, Voit, Voll, Vehreschild, Müller-Ladner and Pfeil.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu